Compass Ion Advisors LLC Acquires New Stake in Axon Enterprise, Inc $AXON

Key Points

• Compass Ion Advisors LLC made a new investment of approximately $830,000 in Axon Enterprise, acquiring 1,003 shares, according to their latest SEC filing.
• A number of institutional investors are actively buying shares of Axon, with overall 79.08% of the company's stock now held by hedge funds and other institutions.
• Analysts are positive on Axon, with thirteen rating it as a Buy and setting price targets ranging from $840 to $1,000, indicating strong growth potential.

Compass Ion Advisors LLC bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 1,003 shares of the biotechnology company's stock, valued at approximately $830,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Fourth Dimension Wealth LLC purchased a new stake in Axon Enterprise in the 4th quarter valued at approximately $30,000. TCTC Holdings LLC raised its position in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock worth $29,000 after buying an additional 24 shares during the period. Bartlett & CO. Wealth Management LLC raised its position in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock worth $31,000 after buying an additional 33 shares during the period. Catalyst Capital Advisors LLC purchased a new position in shares of Axon Enterprise in the 1st quarter worth $32,000. Finally, Banque Transatlantique SA purchased a new position in shares of Axon Enterprise in the 1st quarter worth $31,000. Institutional investors and hedge funds own 79.08% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AXON. Craig Hallum upgraded Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a report on Tuesday, August 5th. Needham & Company LLC set a $870.00 price target on Axon Enterprise and gave the company a "buy" rating in a report on Tuesday, August 5th. JMP Securities increased their price target on Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a report on Tuesday, July 22nd. Wolfe Research began coverage on Axon Enterprise in a report on Monday, July 7th. They issued an "outperform" rating for the company. Finally, Zacks Research downgraded Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $837.69.

Axon Enterprise Stock Up 0.2%

Shares of Axon Enterprise stock traded up $1.39 during trading hours on Monday, hitting $775.92. 406,873 shares of the company's stock traded hands, compared to its average volume of 684,506. The stock has a 50 day simple moving average of $759.97 and a 200-day simple moving average of $696.68. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. The company has a market cap of $60.91 billion, a PE ratio of 191.59, a PEG ratio of 28.43 and a beta of 1.40. Axon Enterprise, Inc has a twelve month low of $388.36 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The company's revenue was up 32.6% on a year-over-year basis. During the same period last year, the firm earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CFO Brittany Bagley sold 870 shares of the firm's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $773.25, for a total value of $672,727.50. Following the transaction, the chief financial officer owned 113,022 shares of the company's stock, valued at $87,394,261.50. This trade represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Hadi Partovi bought 1,358 shares of the business's stock in a transaction on Wednesday, August 13th. The stock was acquired at an average cost of $740.00 per share, for a total transaction of $1,004,920.00. Following the acquisition, the director directly owned 237,938 shares of the company's stock, valued at $176,074,120. The trade was a 0.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 44,932 shares of company stock valued at $34,408,816 over the last ninety days. Insiders own 4.40% of the company's stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.